Skip to main content
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1988 Jan 30;296(6618):316–320.

United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results

Uk-Tia Study Group
PMCID: PMC2544832  PMID: 2894232

Abstract

From 1979 to 1985, 2435 patients thought to have had a transient ischaemic attack or minor ischaemic stroke were allocated at random to receive long term blind treatment with either aspirin 600 mg twice daily (n=815), aspirin 300 mg once daily (806), or placebo (814). Treatment continued with about 85% compliance until September 1986 (mean four years). The odds of suffering one or more of four categories of event—namely, non-fatal myocardial infarction, non-fatal major stroke, vascular death, or non-vascular death—were 18% less in the two groups allocated to receive aspirin than in the group allocated to receive placebo (2p=0·01). The more relevant but less frequent composite event of disabling stroke or vascular death was reduced by only 7%; this reduction was not significantly different from zero, but nor was it significantly different from a 25% reduction. There was no definite difference between responses to the 300 mg and 1200 mg daily doses, except that the lower dose was significantly less gastrotoxic.

Full text

PDF
316

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Heyman A., Wilkinson W. E., Hurwitz B. J., Haynes C. S., Utley C. M., Rosati R. A., Burch J. G., Gore T. B. Risk of ischemic heart disease in patients with TIA. Neurology. 1984 May;34(5):626–630. doi: 10.1212/wnl.34.5.626. [DOI] [PubMed] [Google Scholar]
  2. Patrono C., Ciabattoni G., Patrignani P., Pugliese F., Filabozzi P., Catella F., Davì G., Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985 Dec;72(6):1177–1184. doi: 10.1161/01.cir.72.6.1177. [DOI] [PubMed] [Google Scholar]
  3. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Wiebers D. O., Whisnant J. P., O'Fallon W. M. Reversible ischemic neurologic deficit (RIND) in a community: Rochester, Minnesota, 1955-1974. Neurology. 1982 May;32(5):459–465. doi: 10.1212/wnl.32.5.459. [DOI] [PubMed] [Google Scholar]
  5. Yusuf S., Peto R., Lewis J., Collins R., Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335–371. doi: 10.1016/s0033-0620(85)80003-7. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES